Candidate Pipeline Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter- - MEI Maintains Strong Financial Position with ~$164 Million in Cash- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate prog...

MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter- - MEI Maintains Strong Financial Position with ~$164 Million in Cash- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate prog...

MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights --Multiple Clinical Development Milestones Anticipated in 2021-- --MEI Maintains Strong Financial Position with $180 Million in Cash-- News provided by Share this article Share this article SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2020.  "We remain well positioned and focused on advancing zandelisib toward commercialization to deliver a...